Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTOPICALStandard

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

Standard Dose
0.064%;0.005%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is listed in Drugs@FDA under application 213269 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE Form and strength SUSPENSION;TOPICAL - 0.064%;0.005% Sponsor SUN PHARMA CANADA Submission history Latest submission status date: 2020-09-02 00:00:00.

Structured Monograph

Clinical summary

Approval overview CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is listed in Drugs@FDA under application 213269 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE Form and strength SUSPENSION;TOPICAL - 0.064%;0.005% Sponsor SUN PHARMA CANADA Submission history Latest submission status date: 2020-09-02 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE (BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE) | Drug Monograph | MedicHelpline